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Androgen deficiency in male patients diagnosed
with ANCA-associated vasculitis: a cause of
fatigue and reduced health-related quality of life?
Janneke Tuin1*, Jan-Stephan F Sanders1, Birgit M Buhl2, André P van Beek3 and Coen A Stegeman1
Abstract
Introduction: Low testosterone levels in men are associated with fatigue, limited physical performance and
reduced health-related quality of life (HRQOL); however, this relationship has never been assessed in patients with
anti-neutrophil cytoplasmic antibodies (ANCA) -associated vasculitides (AAV). The aim of this study was to assess
the prevalence of androgen deficiency and to investigate the role of testosterone in fatigue, limited physical
condition and reduced HRQOL in men with AAV.
Methods: Male patients with AAV in remission were included in this study. Fatigue and HRQOL were assessed by
the multi-dimensional fatigue inventory (MFI)-20 and RAND-36 questionnaires.
Results: Seventy male patients with a mean age of 59 years (SD 12) were included. Scores of almost all subscales
of both questionnaires were significantly worse in patients compared to controls. Mean total testosterone and free
testosterone levels were 13.8 nmol/L (SD 5.6) and 256 pmol/L (SD 102), respectively. Androgen deficiency (defined
according to Endocrine Society Clinical Practice Guidelines) was present in 47% of patients. Scores in the subscales
of general health perception, physical functioning and reduced activity were significantly worse in patients with
androgen deficiency compared to patients with normal androgen levels. Testosterone and age were predictors for
the RAND-36 physical component summary in multiple linear regression analysis. Testosterone, age, vasculitis
damage index (VDI) and C-reactive protein (CRP) were associated with the MFI-20 subscale of general fatigue.
Conclusions: This study showed that androgen deficiency was present in a substantial number of patients with
AAV. Testosterone was one of the predictors for physical functioning and fatigue. Testosterone may play a role in
fatigue, reduced physical performance and HRQOL in male patients with AAV.
Keywords: Fatigue, health-related quality of life (HRQOL), physical functioning, testosterone, androgen deficiency,
ANCA-associated vasculitis
Introduction
Granulomatosis with polyangiitis (GPA), microscopic
polyangiitis (MPA) and eosinophilic granulomatosis with
polyangiitis (EGPA) are associated with anti-neutrophil
cytoplasmic antibodies (ANCA) and, therefore, are also
known as ANCA-associated vasculitides (AAV). This
group of autoimmune diseases is characterized by
inflammation of the small to medium-sized blood ves-
sels, which can affect a variety of organs [1]. The upper
airways, lungs and kidneys are most frequently involved
and this may lead to organ failure with potentially life-
threatening outcome. The combination of cyclophospha-
mide (CY) and high dose glucocorticoids (GC) forms the
cornerstone of induction therapy. With this therapy life
expectancy has increased significantly with current five-
year survival rates exceeding 80% [2]. Consequently,
these previously fatal diseases have evolved into chronic
relapsing illnesses.
Fatigue and reduced physical condition are frequently
expressed complaints by patients, even after attainment
of remission. In addition, several studies have demon-
strated that many patients with these diseases experience
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a reduced health-related quality of life (HRQOL) and
impairments in daily life, work and social activities[3,4].
Since these diseases have become chronic diseases, more
attention has been payed to the assessment of HRQOL
and its contributing factors. Pain, presence of neuropa-
thy, glucocorticoid treatment, neurologic involvement at
diagnosis and employement status are considered to
influence HRQOL [4-6]. Fatigue is also thought to be a
major contributor to impaired quality of life [7].
Low testosterone levels are known to be associated
with fatigue and diminished performance. Previously, a
small study reported the prevalence of hypogonadism in
19 male patients with GPA [8]. More than 50% of
patients fulfilled the proposed criteria of hypogonadism
in that study group; however, the relationship between
testosterone and fatigue was not assessed.
The aim of the current study was to investigate the
prevalence and determinants of androgen deficiency in a
large group of men with AAV in stable remission and




Male patients diagnosed with GPA, MPA or EGPA in
stable remission and visiting the outpatient clinic of the
University Medical Center Groningen (UMCG) between
October 2010 and October 2011 were asked to partici-
pate in this cross-sectional study. Patients were eligible
if therapy with cyclophosphamide had been stopped at
least six months prior to study entry. Patients were clas-
sified as GPA, MPA or EGPA according to criteria
adopted from the Chapel Hill Consensus Conference
Nomenclature and the algorithm developed by Watts et
al. [1,9]. Data were collected on patient, disease and
treatment characteristics through medical records.
Informed consent was obtained at the visit to the outpa-
tient clinic. The study was approved by the Medical
Ethical Board of the University Medical Center Gronin-
gen as part of a larger study on biomarkers and disease
activity and damage in ANCA-associated vasculitis
(METc number 2010/057).
Clinical assessment and questionnaires
Disease activity at time of assessment was scored using
the Birmingham Vasculitis Activity Score (BVAS) [10].
Stable remission was defined as BVAS 0 and no signs or
symptoms of disease activity. Chronic damage due to
disease, treatment or unrelated events was scored by the
Vasculitis Damage Index (VDI) at the time of study [11].
For the assessment of HRQOL the RAND- 36 health
survey was used. In this self-report questionnaire
HRQOL is divided into eight subscales: general health
perception, physical functioning, social functioning, role
limitations due to physical problems, role limitations
due to emotional problems, pain, vitality and mental
health. Normative data were derived from a screening of
1,063 persons in the municipality of Emmen in The
Netherlands. Scores in every subscale range from 0 to
100, with a higher score reflecting a higher level of func-
tioning [12]. The eight domains of the RAND-36 were
summarized resulting in the physical component sum-
mary (PCS) and the mental component summary
(MCS), with a population mean of 50 SD 10 [13]. For
the assessment of fatigue the Multi-dimensional Fatigue
Inventory (MFI-20) was used [14]. This self-report ques-
tionnaire contains 20-items, covering five dimensions of
fatigue: general fatigue, physical fatigue, reduced activity,
reduced motivation and mental fatigue. Scores in every
dimension range from 4 to 20, a higher score corre-
sponding to a higher level of fatigue. The subscale of
general fatigue was considered as the overall fatigue
score encompassing both physical and mental aspects of
fatigue, as proposed by the authors [14]. Normative data
were derived from a healthy Dutch population described
by Smets et al. [15]. Both questionnaires were in Dutch.
The study cohort and reference population were not
matched.
Laboratory parameters
All laboratory parameters were measured at the time of
the assessment. Creatinine clearance (CC) was obtained
from 24-hour urine collection; if not available, CC was
estimated using the Cockcroft-Gault formula [16]. Nor-
mal kidney function was defined as CC of >90 ml/min-
ute together with proteinuria of <0.3 g/24 hours.
Total testosterone was analyzed by radioimmunoassay,
using (1,2,6,73H)-testosterone as tracer (Amersham
Biosciences, Buckinghamshire, UK) [17]. The coefficient
of the intra-assay variation was 4.5%, and of the inter-
assay variation was 10.5%. Sex hormone-binding globu-
lin (SHBG) was measured by in-house radioimmunoas-
say, using a binding assay. Hemoglobin and albumin
were obtained from routine blood investigations. SHBG
and albumin were measured to calculate the free testos-
terone from total testosterone according to the formula
by Vermeulen [18].
Definitions
Male patients were considered to have androgen defi-
ciency when the level of total testosterone was <10 nmol/
L or 10 to 12 nmol/L in combination with free testoster-
one <0.30 nmol/L (lower limit UMCG), as recommended
by the Endocrine Society Clinical Practice Guidelines [19].
Statistical analyses
Data were analyzed using SPSS 20.0. Graphs were made
with GraphPad Prism softare (version 5.0) and SigmaPlot
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(version 11.0). Mean plus standard deviation (SD) and
median plus interquartile range (IQR) were used for
summary data. For the comparisons of normally distribu-
ted data the Student’s t-test was used. Not normally dis-
tributed data were compared using the Mann-Whitney
U-test. If indicated, not normally distributed data were
log transformed. Z-scores were calculated for comparison
of the scores of the RAND-36 and the MFI-20 between
patients with androgen deficiency and normal androgen
levels. Backward stepwise multiple linear regression ana-
lyses were performed on PCS, MCS and the subscale of
general fatigue. The following candidate predictors were
included: total testosterone; age; interaction between age
and testosterone; hemoglobin; CC; C-reactive protein
(CRP); VDI; disease duration; log-transformed cumula-
tive GC dose and log-transformed cumulative CY dose.
Backward stepwise multiple linear regression analysis was
also performed on the level of total testosterone. The fol-
lowing candidate predictors were included: age; SHBG;
VDI; body mass index (BMI); hemoglobin; current gluco-
corticoid use; CRP; log-transformed cumulative cyclo-
phosphamide dose and the log-transformed cumulative
glucocorticoid dose. Statistical significance was defined
as a two-sided P ≤ 0.05.
Results
Patient characteristics at diagnosis and study
Seventy male patients diagnosed with GPA (n = 54),
MPA (n = 14) and EGPA (n = 2) between 1984 and 2009
were included. The mean age at diagnosis was 50 years
(SD 14). In five patients the disease was limited to the
ear, nose and throat (ENT) region, eyes, orbita or a com-
bination; in all others generalized vasculitis had been pre-
sent during the course of the disease. The ENT region
(63%), kidneys (56%) and lungs (51%) were most fre-
quently involved. ANCA against proteinase 3 (PR-3)
were present in 50 patients, ANCA against myeloperoxi-
dase (MPO) were present in 18 patients and ANCA with-
out specificity were present in two patients. Sixty-seven
patients had been treated with cyclophosphamide, two
patients with rituximab and one had been treated only
with co-trimoxazole monotherapy prior to this study.
One of the included patients developed a transient reduc-
tion of total testosterone at diagnosis. A second patient
experienced a testicular infarction with extensive hemor-
rhage and inflammation resulting in a one-sided orchi-
dectomy. A third patient had involvement of the testes at
diagnosis. Testosterone levels in all three patients had
returned or were proven to be within the normal range
after induction of remission in a period prior to this
study. None of the included patients was or had been
treated with androgen substitution therapy.
Forty-three patients experienced one or more relapse(s)
and 27 patients had no relapse before inclusion in the
current study. An overview of patient and laboratory char-
acteristics at the time of study is presented in Table 1.
Androgen status
Mean total and free testosterone levels were 13.8 nmol/
L (SD 5.6) and 256 pmol/L (SD 102), respectively
(Figure 1). Thirty-three patients (47%) had androgen
deficiency according to the definition of the Endocrine
Society Clinical Practice Guidelines [19]. Seven percent
of patients under 50 years of age (n = 14) and 57% of
patients over 50 years of age (n = 56) had androgen
deficiency. The mean level of SHBG was 39 nmol/L
(SD 14), and 51 patients (73%) had SHBG levels above
the upper reference of our center, 30 nmol/L. No
known SHBG-increasing conditions, for example, hepa-
tic cirrhosis, hepatitis, hyperthyroidism, use of anticon-
vulsants or HIV, were present in any of our patients
[19]. The use of glucocorticoids at the time of the




Age at study (years), mean (SD) 59 (12)
Diagnosis to study (months), median (IQR) 79 (44 to 149)
Last relapse to study (months), median (IQR) 39 (19 to 68)
BVAS = 0, n 70
VDI, median (IQR) 3 (2 to 4)
Cum. CY (g.), median (IQR) 27.5 (17.2 to 57.8)
Cum. GC (g.), median (IQR) 15.3 (7.0 to 26.0)
TT (nmol/L), mean (SD) 13.8 (5.6)
FT (pmol/L), mean (SD) 256 (102)
SHBG (nmol/L), mean (SD) 39 (14)
Hb (mmol/L), mean (SD) 8.7 (1.0)
CRP (mg/L), median (IQR) <5 (<5 to 6)
CC (ml/min), mean (SD) 90 (30)
BVAS, Birmingham Vasculitis Activity Score; CC, creatinine clearance; CRP, C-
reactive protein; Cum. CY, cumulative cyclophosphamide; Cum. GC, cumulative
glucocorticoid; FT, free testosterone; Hb, hemoglobin; SHBG, sex hormone-
binding globulin; TT, total testosterone; VDI, Vasculitis Damage Index.
Figure 1 Mean total and free testosterone. Normal values are
represented by the dashed lines, respectively, at 10 nmol/L for total
testosterone and 300 pmol/L for free testosterone.
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assessment was significantly associated with lower levels
of SHBG, a known effect of glucocorticoid use.
Scores on the RAND-36 and MFI-20
Scores in every subscale of the RAND-36, except for the
subscale of mental health, were significantly lower in
patients with AAV compared to the control population (P
values ranged from < 0.001 to 0.009) (see Figure 2). The
mean PCS score was 41.4 (SD 11.4) which is significantly
lower than in the mean population (P < 0.001). The mean
MCS score was 47.8 (SD 9.5) which is not significantly
lower than that of the mean population (P = 0.055).
Scores in the subscales of general fatigue (P = 0.001), phy-
sical fatigue (P < 0.001) and reduced activity (P = 0.001) of
the MFI-20 were significantly higher compared to the refer-
ence scores. The subscales of reduced motivation and men-
tal fatigue were not significantly higher (see Figure 3).
Z-scores of the PCS, subscale of general health per-
ception and subscale of physical functioning (RAND-36)
were significantly lower and scores in the subscale of
reduced activity (MFI-20) were significantly higher in
patients with androgen deficiency compared to patients
with normal androgen levels. In addition, scores in the
subscales of social functioning (P = 0.052), role limita-
tions due to physical problems (P = 0.081), general fati-
gue (P = 0.081), physical fatigue (P = 0.062) and
reduced motivation (P = 0.064) tended to be worse in
patients with androgen deficiency (see Figure 4). The
patient characteristics for patients with (n = 33) and
without (n = 37) androgen deficiency are presented in
Table 2. Additional file 1, Table S1 shows a broad
overview of scores of the RAND-36 and MFI-20
questionnaires.
The predictors for physical functioning (PCS), mental
functioning (MCS) and fatigue (subscale of general fati-
gue) were assessed in multiple linear regression analyses.
Testosterone, age and the interaction between age and
testosterone were predictors for the PCS (see Table 3).
The subscale of general fatigue was associated with tes-
tosterone, age, the interaction between age and testos-
terone, CRP and VDI (see Table 4). None of the
candidate predictors was significantly associated with
the MCS. Figure 5 demonstrates the nature of the inter-
action between age and testosterone levels on PCS.
Determinants of levels of testosterone
Patients with androgen deficiency had a significantly
longer disease duration, higher VDI scores and higher
cumulative cyclophosphamide doses compared to
patients with normal androgen levels, reflecting a higher
disease burden and more immunosuppressive therapy
(Table 2).
In multiple linear regression analysis total testosterone
was significantly associated with the predictors age,
SHBG and the log transformed cumulative glucocorti-
coid dose (Table 5).
Discussion
Fatigue and limited physical condition are frequently
expressed complaints by patients with AAV. Our data
confirm the finding that AAV patients show consider-
ably reduced HRQOL and increased fatigue. Several stu-
dies identified contributing factors to reduced HRQOL
and fatigue; however, the role of sex hormones has not
been studied. Here, we showed that there was a high
prevalence of androgen deficiency among male patients
with AAV and that testosterone levels were associated
Figure 2 Mean scores in the subscales of the RAND-36 of all
patients and references. A P value of P < 0.010 is shown as * and
P < 0.001 as **.
Figure 3 Mean scores in the subscales of the MFI-20 of all
patients and references. A P value of P < 0.010 is shown as * and
P < 0.001 as **.
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Figure 4 Z-scores of the RAND-36 and MFI-20 questionnaires. Grey circles represent mean and SD of patients with normal androgen levels
(n = 37) and black squares represent mean and SD of patients with androgen deficiency (n = 33). Mean population score is represented by a Z-
score of zero. P < 0.05 is indicated with *. Note that higher Z-scores on the MFI-20 mean more fatigue and lower Z-scores on the RAND-36
signify poorer quality of life.
Table 2 Patient, treatment and laboratory characteristics of patients with androgen deficiency and patients with
normal androgen levels





Age at study (years), mean (SD) 55 (13) 64 (10) 0.005
Diagnosis to study (months), median (IQR) 75 (39 to 119) 129 (70 to 168) 0.041
Last relapse to study (months), median (IQR) 36 (19 to 67) 49 (19 to 73) 0.403
BVAS = 0, n 37 33
VDI, median (IQR) 3 (2 to 4) 4 (2 to 5) 0.045
Cum. CY (g.), median (IQR) 22.4 (15.5 to 39.8) 46.6 (18.0 to 92.0) 0.049
Cum. GC (g.), median (IQR) 10.6 (6.1 to 18.4) 21.7 (13.5 to 33.0) 0.001
TT (nmol/L), mean (SD) 17.4 (5.5) 9.8 (1.9) <0.001
FT (pmol/L), mean (SD) 313 (103) 193 (51) <0.001
SHBG (nmol/L), mean (SD) 43 (12) 35 (15) 0.029
Hb (mmol/L), mean (SD) 9.0 (1.0) 8.4 (0.9) 0.009
CRP (mg/L), median (IQR) <5 (<5 to <5) <5 (<5 to 9) 0.072
CC (ml/min), mean (SD) 91 (27) 89 (39) 0.811
Treatment at study
No treatment, number 11 7
CT, number 9 5
GC (+ CT), number 3 (1) 7 (2)
Aza (+CT), number 8 (6) 2 (1)
MMF (+CT), number 3 (3) 2 (1)
GC and Aza (+CT), number 1 (1) 6 (6)
GC and MMF (+CT), number 2 (2) 4 (3)
Aza, azathioprine; BVAS, Birmingham Vasculitis Activity Score; CC, creatinine clearance; CRP, C-reactive protein; CT, co-trimoxazole, 2 dd 800/160 mg; Cum. CY,
cumulative cyclophosphamide; Cum. GC, cumulative glucocorticoid; FT, free testosterone; Hb, hemoglobin; MMF, mycophenolate mofetil; SHBG, sex hormone-
binding globulin; TT, total testosterone; VDI, Vasculitis Damage Index.
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with physical functioning and fatigue in multiple linear
regression analyses. Furthermore, we found indications
that longer duration of disease and treatment, especially
long-term use of glucocorticoids, was associated with
reduced androgen concentrations in male patients with
AAV.
Androgen deficiency was more prevalent in this study
(47%) compared to the normal population [20]. Aging is
associated with a decline of testosterone levels; however,
this physiological decline is rather subtle and is esti-
mated to be -0.4% to -0.8% per year in cross-sectional
studies [21,22]. Patients with androgen deficiency were
significantly older compared to patients with normal
androgen levels, and, therefore, an age-related decline of
a few percent was expected. However, testosterone levels
in patients with androgen deficiency were more than
40% lower.
Besides age and SHBG, the cumulative glucocorticoid
dose was associated with the level of total testosterone,
suggesting a role for treatment with glucocorticoids in
this decline. It is unknown whether glucocorticoids
themselves, as toxic drugs, reduce androgen production
or whether a higher cumulative dose reflects severe dis-
ease, which may be associated with reduced testosterone
production. Previous research showed that chronic glu-
cocorticoid therapy can result in a decrease of testoster-
one [23-26]. In addition, disease related damage
reflected by the VDI, disease duration and the cumula-
tive cyclophosphamide dose were significantly higher in
patients with androgen deficiency. These variables, espe-
cially the cumulative cyclophosphamide dose, were not
significantly associated with levels of testosterone in
multiple linear regression analyses. Over time, the
cumulative cyclophosphamide dose has been reduced;
therefore, a possible relation between cyclophosphamide
and testosterone might be difficult to demonstrate.
Our findings are in line with the findings of Richter et
al. who reported a high prevalence of hypogonadism in
a small cohort of male patients with AAV [8]. In con-
trast to Richter et al., we found indications that the
cumulative glucocorticoid doses were associated with
levels of testosterone. It is not clear what caused the
opposite finding; however, our cohort consisted of more
patients, patients had a longer disease duration and
twice as high median cumulative glucocorticoid doses.
To our knowledge, Richter et al. were the first to report
data on sex hormones in a cohort of men with AAV; in
patients with rheumatoid arthritis (RA) and systemic
lupus erythematosus (SLE) sex hormones have been stu-
died before. In RA several studies reported low levels of
testosterone, often with an increase of testosterone after
attaining remission [27-29]. In SLE the results are not
conclusive, with some studies showing suppression of
testosterone levels and some not [30]. However, both
disease courses and treatment strategies are different
from AAV.
Finally, SHBG was raised in over 70% of patients, pos-
sibly due to raised production of SHBG in the liver in
response to low levels of free testosterone. Levels of free
Table 3 Multiple linear regression model predicting
for PCS
PCS B (95% CI) P value
Age, years -0.917 (-1.569; -0.266) 0.007
Total testosterone, nmol/L -2.837 (-5.293; -0.381) 0.024
Interaction age and total testosterone 0.57 (0.013; 0.102) 0.013
Adjusted R square 0.092; intercept 89.32 (95% CI, 51.572; 127.071). PCS,
physical component summary.
Table 4 Multiple linear regression model predicting for
general fatigue
General fatigue B (95% CI) P value
Age, years 0.301 (0.026; 0.575) 0.032
Total testosterone, nmol/L 1.045 (0.017; 2.073) 0.046
Interaction age and total testosterone -0.019 (-0.038; 0.000) 0.045
VDI 0.642 (0.061; 1.223) 0.031
CRP -0.123 (-0.238; -0.008) 0.037
Adjusted R square; 0.117 intercept -6.523 (95% CI, -22.426; 9.380). CRP, C-
reactive protein; VDI, Vasculitis Damage Index.
Figure 5 Association between the physical component score
and levels of total testosterone for patients under and above
the median age of 61.3 years. Open squares represent total
testosterone levels and PCS scores of patients under the median
age and the blue circles represent total testosterone levels and PCS
scores of patients above the median age. PCS, physical component
summary.
Table 5 Multiple linear regression model predicting for
level of total testosterone
B (95% CI) P value
Age, years -0,15 (-0.25; -0.06) 0.002
SHBG, nmol/L 0,16 (0.07; 0.24) 0.000
Ln cum GC -1,89 (-3.38; -0.40) 0.014
Adjusted R square 0.302; intercept 34.92 (95% CI, 19.16; 50.68). Ln cum GC,
log-transformed cumulative glucocorticoid dose; SHBG, sex hormone-binding
globulin;
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testosterone, which are biologically active, decrease due
to binding of SHBG and, subsequently, relatively normal
total testosterone levels are measured. This could even
underestimate the number of patients with androgen
deficiency in a patient population in which only total
testosterone levels are measured.
Scores of the RAND-36 and the MFI-20 of patients
were significantly worse compared to the control popu-
lation, except for the subscales of mental health
(RAND-36), reduced motivation and mental fatigue
(MFI-20). This finding is consistent with the studies of
Koutantji et al. [5] and Basu et al. [7], in which the sub-
scale of mental health of the SF-36 was not significantly
reduced. Patients with androgen deficiency scored worse
on several subscales of both questionnaires; however,
this difference was most evident in subscales reflecting
physical functioning, including the PCS. In addition,
total testosterone was an important predictor for physi-
cal functioning, especially in older patients. Total testos-
terone, age, VDI and CRP were predictors for fatigue.
This demonstrates that both testosterone and damage
due to disease activity may play a role in fatigue. In con-
clusion, this suggests an influence of testosterone on
physical performance and fatigue in male patients with
AAV.
Our study has several limitations. Fatigue and reduced
HRQOL are multifactorial problems and the group of
patients is too small to identify all the contributors to
these problems. This heterogeneous cohort consisted of
patients diagnosed with GPA, MPA and EGPA. With
only two EGPA patients, this cohort is probably not
representative of patients with EGPA. Additionally, fati-
gue is also a common complaint among female patients,
but they have been excluded from this study, due to the
focus on testosterone.
We measured the testosterone levels only once and we
did not measure levels of luteinizing hormone (LH) or
follicle stimulating hormone (FSH). Therefore, further
research is needed to specify if the low testosterone
levels are caused by primary testicular failure, by hypo-
pituitary hypogonadism or by a combination of both.
Furthermore, we have not evaluated other relevant con-
sequences resulting from low levels of testosterone in
this study, in particular sexual dysfunction, which might
be more strongly associated with testosterone levels
than fatigue is [31].
Conclusions
This study showed that a substantial number of male
patients with AAV in remission have androgen defi-
ciency. Furthermore, we demonstrated that reduced
levels of testosterone were associated with reduced phy-
sical performance and increased fatigue. Since testoster-
one is one of the few contributing factors that could be
modified, testosterone substitution might be considered
in these patients.
We also found evidence that treatment with glucocor-
ticoids might influence androgen production in male
patients with AAV. Our findings stress the need for new
therapies with less toxic drugs which could not only
replace cyclophosphamide but also reduce the need for
treatment with glucocorticoids.
Further research should study the effect of testoster-
one substitution on fatigue, physical performance and
health-related quality of life in male patients with AAV.
Additional material
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List of abbreviations
AAV: ANCA-associated vasculitides; ANCA: anti-neutrophil cytoplasmic
antibodies; BVAS: Birmingham Vasculitis Activity Score; CC: creatinine
clearance; CRP: C-reactive protein; CY: cyclophosphamide; EGPA: eosinophilic
granulomatosis with polyangiitis; ENT: ear, nose and throat; FSH: follicle
stimulating hormone; GC: glucocorticoid; GPA: granulomatosis with
polyangiitis; HRQOL: health-related quality of life; LH: luteinizing hormone;
MCS: mental component summary; MFI-20: Multi-dimensional Fatigue
Inventory; MPA: microscopic polyangiitis; MPO: myeloperoxidase; PCS:
physical component summary; PR-3: proteinase 3; RA: rheumatoid arthritis;
SHBG: sex hormone-binding globulin; SLE: systemic lupus erythematosus;
UMCG: University Medical Center Groningen; VDI: Vasculitis Damage Index.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JT, BB, JS, CS and AB all contributed to the conception and design of the
study. JT and BB collected the data necessary for this study and JT, BB, JS,
CS and AB made substantial contributions to the analyses and interpretation
of the data. JT, BB, JS, CS and AB contributed to the drafting and revising of
the content of the manuscript. All authors read and approved the final
manuscript.
Authors’ details
1Department of Internal Medicine, Division of Nephrology, University of
Groningen, University Medical Center Groningen, The Netherlands.
2Department of Internal Medicine, Division of Rheumatology, University of
Groningen, University Medical Center Groningen, The Netherlands.
3Department of Internal Medicine, Division of Endocrinology, University of
Groningen, University Medical Center Groningen, The Netherlands.
Received: 4 December 2012 Revised: 12 July 2013
Accepted: 12 September 2013 Published: 12 September 2013
References
1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF,
Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG,
Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA,
Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH,
Takahashi K, Watts RA: 2012 revised International Chapel Hill Consensus
Conference Nomenclature of Vasculitides. Arthritis Rheum 2013, 65:1-11.
2. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW,
Gross WL, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott D,
Witter J, Yazici H, Luqmani RA, European Vasculitis Study Group (EUVAS):
Outcomes from studies of antineutrophil cytoplasm antibody associated
vasculitis: a systematic review by the European League Against
Tuin et al. Arthritis Research & Therapy 2013, 15:R117
http://arthritis-research.com/content/15/5/R117
Page 7 of 8
Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008,
67:1004-1010.
3. Hoffman GS, Drucker Y, Cotch MF, Locker GA, Easley K, Kwoh K: Wegener’s
granulomatosis: patient-reported effects of disease on health, function,
and income. Arthritis Rheum 1998, 41:2257-2262.
4. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gutfleisch J, Peter HH,
Raspe HH, Gross WL: Effect of Wegener’s granulomatosis on work
disability, need for medical care, and quality of life in patients younger
than 40 years at diagnosis. Arthritis Rheum 2002, 47:320-325.
5. Koutantji M, Harrold E, Lane SE, Pearce S, Watts RA, Scott DG: Investigation
of quality of life, mood, pain, disability, and disease status in primary
systemic vasculitis. Arthritis Rheum 2003, 49:826-837.
6. Walsh M, Mukhtyar C, Mahr A, Herlyn K, Luqmani R, Merkel PA, Jayne DR:
Health-related quality of life in patients with newly diagnosed
antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care
Res (Hoboken) 2011, 63:1055-1061.
7. Basu N, Jones GT, Fluck N, MacDonald AG, Pang D, Dospinescu P, Reid DM,
Macfarlane GJ: Fatigue: a principal contributor to impaired quality of life
in ANCA-associated vasculitis. Rheumatology (Oxford) 2010, 49:1383-1390.
8. Richter JG, Becker A, Specker C, Schneider M: Hypogonadism in Wegener’s
granulomatosis. Scand J Rheumatol 2008, 37:365-369.
9. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A,
Segelmark M, Cohen-Tervaert JW, Scott D: Development and validation of
a consensus methodology for the classification of the ANCA-associated
vasculitides and polyarteritis nodosa for epidemiological studies. Ann
Rheum Dis 2007, 66:222-227.
10. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, Savage C,
Adu D: Birmingham Vasculitis Activity Score (BVAS) in systemic
necrotizing vasculitis. QJM 1994, 87:671-678.
11. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, Adu D:
Development and initial validation of the Vasculitis Damage Index for
the standardized clinical assessment of damage in the systemic
vasculitides. Arthritis Rheum 1997, 40:371-380.
12. VanderZee KI, Sanderman R, Heyink JW, de Haes H: Psychometric qualities
of the RAND 36-Item Health Survey 1.0: a multidimensional measure of
general health status. Int J Behav Med 1996, 3:104-122.
13. Ware JE, Koskinski M, Keller S: SF-36 Physical and Mental Health Summary
Scales: A User’s Manual. 2 edition. Boston, MA: The Health Institute; 1994.
14. Smets EM, Garssen B, Bonke B, De Haes JC: The Multidimensional Fatigue
Inventory (MFI) psychometric qualities of an instrument to assess
fatigue. J Psychosom Res 1995, 39:315-325.
15. Smets EM, Visser MR, Willems-Groot AF, Garssen B, Schuster-Uitterhoeve AL,
de Haes JC: Fatigue and radiotherapy: (B) experience in patients 9
months following treatment. Br J Cancer 1998, 78:907-912.
16. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum
creatinine. Nephron 1976, 16:31-1641.
17. Pratt JJ, Wiegman T, Lappohn-a RE, Woldring MG: Estimation of plasma
testosterone without extraction and chromatography. Clin Chim Acta
1975, 59:337-346.
18. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple
methods for the estimation of free testosterone in serum. J Clin
Endocrinol Metab 1999, 84:3666-3672.
19. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ,
Swerdloff RS, Montori VM, Task Force Endocrine Society: Testosterone
therapy in men with androgen deficiency syndromes: an Endocrine
Society clinical practice guideline. J Clin Endocrinol Metab 2010,
95:2536-2559.
20. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, Baltimore
Longitudinal Study of Aging: Longitudinal effects of aging on serum total
and free testosterone levels in healthy men. Baltimore Longitudinal
Study of Aging. J Clin Endocrinol Metab 2001, 86:724-731.
21. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G,
Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M,
Boonen S, Vanderschueren D, European Male Aging Study Group:
Hypothalamic-pituitary-testicular axis disruptions in older men are
differentially linked to age and modifiable risk factors: the European
Male Aging Study. J Clin Endocrinol Metab 2008, 93:2737-2745.
22. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD,
Bremner WJ, McKinlay JB: Age trends in the level of serum testosterone
and other hormones in middle-aged men: longitudinal results from the
Massachusetts male aging study. J Clin Endocrinol Metab 2002, 87:589-598.
23. Schaison G, Durand F, Mowszowicz I: Effect of glucocorticoids on plasma
testosterone in men. Acta Endocrinol (Copenh) 1978, 89:126-131.
24. Reid IR, Ibbertson HK, France JT, Pybus J: Plasma testosterone
concentrations in asthmatic men treated with glucocorticoids. Br Med J
(Clin Res Ed) 1985, 291:574.
25. MacAdams MR, White RH, Chipps BE: Reduction of serum testosterone
levels during chronic glucocorticoid therapy. Ann Intern Med 1986,
104:648-651.
26. Kamischke A, Kemper DE, Castel MA, Luthke M, Rolf C, Behre HM,
Magnussen H, Nieschlag E: Testosterone levels in men with chronic
obstructive pulmonary disease with or without glucocorticoid therapy.
Eur Respir J 1998, 11:41-45.
27. Gordon D, Beastall GH, Thomson JA, Sturrock RD: Prolonged
hypogonadism in male patients with rheumatoid arthritis during flares
in disease activity. Br J Rheumatol 1988, 27:440-444.
28. Tengstrand B, Carlstrom K, Hafstrom I: Gonadal hormones in men with
rheumatoid arthritis–from onset through 2 years. J Rheumatol 2009,
36:887-892.
29. Spector TD, Ollier W, Perry LA, Silman AJ, Thompson PW, Edwards A: Free
and serum testosterone levels in 276 males: a comparative study of
rheumatoid arthritis, ankylosing spondylitis and healthy controls. Clin
Rheumatol 1989, 8:37-41.
30. McMurray RW, May W: Sex hormones and systemic lupus erythematosus:
review and meta-analysis. Arthritis Rheum 2003, 48:2100-2110.
31. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G,
Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N,
Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT, EMAS
Group: Identification of late-onset hypogonadism in middle-aged and
elderly men. N Engl J Med 2010, 363:123-135.
doi:10.1186/ar4297
Cite this article as: Tuin et al.: Androgen deficiency in male patients
diagnosed with ANCA-associated vasculitis: a cause of fatigue and
reduced health-related quality of life? Arthritis Research & Therapy 2013
15:R117.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tuin et al. Arthritis Research & Therapy 2013, 15:R117
http://arthritis-research.com/content/15/5/R117
Page 8 of 8
